Highlights of the 3-Year ALTERRA Analysis
The long-term results from the pooled ALTERRA trials provide robust evidence for the use of the Alterra Adaptive Prestent in conjunction with the SAPIEN 3 transcatheter heart valve (THV). Key findings include:
- 97.3% freedom from reintervention at the 3-year mark, suggesting high procedural durability.
- 100% of patients maintained a mean right ventricular outflow tract (RVOT) gradient below 35 mm Hg.
- 93.3% of the cohort exhibited mild or lesser total pulmonary regurgitation (PR) at the 3-year follow-up.
- Zero reported cases of endocarditis, coronary artery compression, or hemopericardium throughout the study period.
